Skip to main content
. 2018 Jun 4;16(2):2097–2104. doi: 10.3892/ol.2018.8891

Figure 3.

Figure 3.

Effects of miR-10b on p-AKT expression in TGF-β-treated and Twist-overexpressed MCF10A cells. (A) miR-10b expression was detected in TGF-β-treated and Twist-overexpressed MCF10A cells and presented as fold-changes. **P<0.01, ***P<0.001 vs. MCF10A. (B) Western blot analysis of FUT8, p-AKT and AKT, detected in Twist-overexpressed MCF10A cells. (C) TGF-β-treated and Twist-overexpressed MCF10A cells were subjected to wound healing and transwell assay ± inhibitor of miR-10b. **P<0.01; ***P<0.001 vs. TGF-β-treated or Twist-overexpressed MCF10A cells. (D) Proliferation analysis in TGF-β-treated and Twist-overexpressed MCF10A cells ± inhibitor of miR-10b. (E) Western blot analysis of FUT8, p-AKT and AKT protein in Twist-overexpressed MCF10A cells, ± inhibitor of miR-10b. (F) Western blot analysis of EMT markers, FUT8, p-AKT and AKT, detected in TGF-β-treated MCF10A cells, ± inhibitor of miR-10b. (Scale bar, 200 µm; ×100 magnification). p-AKT, phospho- protein kinase B; TGF-β, transforming growth factor-β; FUT8, fucosyltranferase; p-AKT, phosphorylated protein kinase B; AKT, protein kinase B; EMT, epithelial-mesenchymal transition; miR, microRNA.